CURXNasdaq

Curanex Pharmaceuticals Inc

Healthcare·Cardiovascular·Commercial·Jericho, NY, United States
CardiovascularMetabolic

Curanex Pharmaceuticals Inc (CURX): 5 pipeline candidates · ~16 mo cash runway · 1 clinical trial. Updated within the last hour.

8.3/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway4.6

16.4 months

Financial Health9.9

D/E 0.04 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Curanex Pharmaceuticals Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$9.1M

Cash

$4.0M

Quarterly Burn

$955K

Runway

16.4 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2027
Today~18 mo out
Catalyst within runway

Pipeline (5 candidates)

DrugPhase
naltrexone-bupropion combinationPhase 4
Phyto-NPreclinical
silenorApproved
silenorApproved
treximetApproved

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

8

Total value held

$168K

HolderSharesValue
geode capital management, llc111,130$57K
two sigma securities, llc56,651$29K
xtx topco ltd51,289$26K
citadel advisors llc50,559$26K
two sigma investments, lp20,254$10K
citigroup inc19,332$10K
jump financial, llc10,551$5K
ubs group ag7,995$4K
1 clinical trial·CEO: Mr. Jun Liu

Frequently asked questions

How many drug candidates are in Curanex Pharmaceuticals Inc's pipeline?

Curanex Pharmaceuticals Inc (CURX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Curanex Pharmaceuticals Inc's lead drug candidate?

Curanex Pharmaceuticals Inc's most advanced tracked candidate is naltrexone-bupropion combination (Phase 4) for Obesity.

What is Curanex Pharmaceuticals Inc's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Curanex Pharmaceuticals Inc has approximately 16.4 months of cash runway.

What is Curanex Pharmaceuticals Inc's market capitalization?

Curanex Pharmaceuticals Inc's market capitalization is approximately $9.1M.

Who is the CEO of Curanex Pharmaceuticals Inc?

Mr. Jun Liu is the chief executive officer of Curanex Pharmaceuticals Inc (CURX).

Get the full picture on Curanex Pharmaceuticals Inc

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.